{
"info": {
"nct_id": "NCT00962091",
"official_title": "An Open-label, Phase 1 Study of the Relative Bioavailability, Food Effect, Safety and Tolerability of MLN8237 in Patients With Advanced Solid Tumors",
"inclusion_criteria": "Each participant must meet all of the following inclusion criteria to be enrolled in the study:\n\n* 18 years or older\n* Histologically or cytologically confirmed metastatic and/or advanced solid tumor\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse\n* Male participants who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse\n* Voluntary written consent\n* Suitable venous access for study-required blood sampling\n* Measurable disease\n* Recovered from effects of prior antineoplastic therapy\n* Meet required entry laboratory and organ function levels\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "Participants meeting any of the following exclusion criteria are not to be enrolled in the study:\n\n* Female participants who are pregnant or lactating\n* Serious medical or psychiatric illness that could interfere with protocol completion\n* Major surgery within 14 days of first dose of alisertib\n* Antineoplastic therapy, radiation therapy or any experimental therapy 21 days prior to first dose of alisertib\n* Nitrosoureas or mitomycin-C within 6 weeks before the first dose of alisertib.\n* Autologous stem cell transplant within 3 months before the first dose of alisertib, or prior allogeneic stem cell transplant at any time.\n* Active infection requiring systemic therapy, or other serious infection\n* Inability to swallow oral medication\n* Gastrointestinal (GI) disease or GI procedure that could interfere with oral absorption or tolerance of alisertib\n* Symptomatic brain metastasis\n* Uncontrolled cardiovascular condition\n* Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected\n* Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C\n* Lactose-intolerant (Parts A and B only)\n* Prior history of metabolic acidosis (Parts A and B only)\n* Use of enzyme-inducing antiepileptic drugs such as phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort within 14 days prior to the first dose of alisertib\n* A medical condition requiring use of pancreatic enzymes; or daily, chronic , or regular use of proton pump inhibitors (PPI); or histamine (H2) receptor antagonists. Participants who intermittently use these medications must meet the following:\n\n * No use of PPI within 7 days of first dose of alisertib\n * No use of H2 antagonist or pancreatic enzymes within 24 hours of first dose of alisertib\n* Participants requiring full systemic anticoagulation",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "* 18 years or older",
"criterions": [
{
"exact_snippets": "18 years or older",
"criterion": "age",
"requirement": {
"requirement_type": "N/A",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
}
]
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "18 years or older",
"criterion": "age",
"requirement": {
"requirement_type": "N/A",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
}
]
}
}
}
]
}
},
{
"identified_line": {
"line": "* Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse",
"criterions": [
{
"exact_snippets": "Female participants",
"criterion": "gender",
"requirement": {
"requirement_type": "value",
"expected_value": "female"
}
},
{
"exact_snippets": "post menopausal",
"criterion": "menopausal status",
"requirement": {
"requirement_type": "status",
"expected_value": "post menopausal"
}
},
{
"exact_snippets": "surgically sterile",
"criterion": "surgical sterility",
"requirement": {
"requirement_type": "status",
"expected_value": "surgically sterile"
}
},
{
"exact_snippets": "agree to practice 2 effective methods of contraception",
"criterion": "contraception methods",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "methods"
}
}
},
{
"exact_snippets": "abstain from heterosexual intercourse",
"criterion": "sexual activity",
"requirement": {
"requirement_type": "activity",
"expected_value": "abstain from heterosexual intercourse"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Female participants",
"criterion": "gender",
"requirement": {
"requirement_type": "value",
"expected_value": "female"
}
},
{
"or_criteria": [
{
"exact_snippets": "post menopausal",
"criterion": "menopausal status",
"requirement": {
"requirement_type": "status",
"expected_value": "post menopausal"
}
},
{
"exact_snippets": "surgically sterile",
"criterion": "surgical sterility",
"requirement": {
"requirement_type": "status",
"expected_value": "surgically sterile"
}
},
{
"or_criteria": [
{
"exact_snippets": "agree to practice 2 effective methods of contraception",
"criterion": "contraception methods",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "methods"
}
}
},
{
"exact_snippets": "abstain from heterosexual intercourse",
"criterion": "sexual activity",
"requirement": {
"requirement_type": "activity",
"expected_value": "abstain from heterosexual intercourse"
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "* Male participants who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse",
"criterions": [
{
"exact_snippets": "Male participants",
"criterion": "gender",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "male"
}
},
{
"exact_snippets": "agree to practice effective barrier contraception",
"criterion": "contraception practice",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "effective barrier contraception"
}
},
{
"exact_snippets": "agree to abstain from heterosexual intercourse",
"criterion": "sexual abstinence",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "abstain from heterosexual intercourse"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Male participants",
"criterion": "gender",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "male"
}
},
{
"or_criteria": [
{
"exact_snippets": "agree to practice effective barrier contraception",
"criterion": "contraception practice",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "effective barrier contraception"
}
},
{
"exact_snippets": "agree to abstain from heterosexual intercourse",
"criterion": "sexual abstinence",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "abstain from heterosexual intercourse"
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
},
{
"identified_line": {
"line": "Each participant must meet all of the following inclusion criteria to be enrolled in the study:",
"criterions": []
},
"logical_structure": {
"and_criteria": []
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* Female participants who are pregnant or lactating",
"criterions": [
{
"exact_snippets": "Female participants",
"criterion": "gender",
"requirement": {
"requirement_type": "value",
"expected_value": "female"
}
},
{
"exact_snippets": "pregnant",
"criterion": "pregnancy status",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "lactating",
"criterion": "lactation status",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Female participants",
"criterion": "gender",
"requirement": {
"requirement_type": "value",
"expected_value": "female"
}
},
{
"or_criteria": [
{
"exact_snippets": "pregnant",
"criterion": "pregnancy status",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "lactating",
"criterion": "lactation status",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "* Serious medical or psychiatric illness that could interfere with protocol completion",
"criterions": [
{
"exact_snippets": "Serious medical ... illness that could interfere with protocol completion",
"criterion": "serious medical illness",
"requirement": {
"requirement_type": "severity",
"expected_value": "serious"
}
},
{
"exact_snippets": "Serious medical ... illness that could interfere with protocol completion",
"criterion": "serious medical illness",
"requirement": {
"requirement_type": "impact on protocol completion",
"expected_value": true
}
},
{
"exact_snippets": "Serious ... psychiatric illness that could interfere with protocol completion",
"criterion": "serious psychiatric illness",
"requirement": {
"requirement_type": "severity",
"expected_value": "serious"
}
},
{
"exact_snippets": "Serious ... psychiatric illness that could interfere with protocol completion",
"criterion": "serious psychiatric illness",
"requirement": {
"requirement_type": "impact on protocol completion",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Serious medical ... illness that could interfere with protocol completion",
"criterion": "serious medical illness",
"requirement": {
"requirement_type": "severity",
"expected_value": "serious"
}
},
{
"exact_snippets": "Serious medical ... illness that could interfere with protocol completion",
"criterion": "serious medical illness",
"requirement": {
"requirement_type": "impact on protocol completion",
"expected_value": true
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Serious ... psychiatric illness that could interfere with protocol completion",
"criterion": "serious psychiatric illness",
"requirement": {
"requirement_type": "severity",
"expected_value": "serious"
}
},
{
"exact_snippets": "Serious ... psychiatric illness that could interfere with protocol completion",
"criterion": "serious psychiatric illness",
"requirement": {
"requirement_type": "impact on protocol completion",
"expected_value": true
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Major surgery within 14 days of first dose of alisertib",
"criterions": [
{
"exact_snippets": "Major surgery within 14 days of first dose of alisertib",
"criterion": "major surgery",
"requirement": {
"requirement_type": "time since",
"expected_value": {
"operator": "<=",
"value": 14,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Major surgery within 14 days of first dose of alisertib",
"criterion": "major surgery",
"requirement": {
"requirement_type": "time since",
"expected_value": {
"operator": "<=",
"value": 14,
"unit": "days"
}
}
}
}
},
{
"identified_line": {
"line": "* Antineoplastic therapy, radiation therapy or any experimental therapy 21 days prior to first dose of alisertib",
"criterions": [
{
"exact_snippets": "Antineoplastic therapy ... 21 days prior to first dose of alisertib",
"criterion": "antineoplastic therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 21,
"unit": "days"
}
}
},
{
"exact_snippets": "radiation therapy ... 21 days prior to first dose of alisertib",
"criterion": "radiation therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 21,
"unit": "days"
}
}
},
{
"exact_snippets": "any experimental therapy 21 days prior to first dose of alisertib",
"criterion": "experimental therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 21,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Antineoplastic therapy ... 21 days prior to first dose of alisertib",
"criterion": "antineoplastic therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 21,
"unit": "days"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "radiation therapy ... 21 days prior to first dose of alisertib",
"criterion": "radiation therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 21,
"unit": "days"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "any experimental therapy 21 days prior to first dose of alisertib",
"criterion": "experimental therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 21,
"unit": "days"
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Autologous stem cell transplant within 3 months before the first dose of alisertib, or prior allogeneic stem cell transplant at any time.",
"criterions": [
{
"exact_snippets": "Autologous stem cell transplant within 3 months before the first dose of alisertib",
"criterion": "autologous stem cell transplant",
"requirement": {
"requirement_type": "time since procedure",
"expected_value": {
"operator": "<",
"value": 3,
"unit": "months"
}
}
},
{
"exact_snippets": "prior allogeneic stem cell transplant at any time",
"criterion": "allogeneic stem cell transplant",
"requirement": {
"requirement_type": "prior occurrence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Autologous stem cell transplant within 3 months before the first dose of alisertib",
"criterion": "autologous stem cell transplant",
"requirement": {
"requirement_type": "time since procedure",
"expected_value": {
"operator": "<",
"value": 3,
"unit": "months"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "prior allogeneic stem cell transplant at any time",
"criterion": "allogeneic stem cell transplant",
"requirement": {
"requirement_type": "prior occurrence",
"expected_value": true
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Active infection requiring systemic therapy, or other serious infection",
"criterions": [
{
"exact_snippets": "Active infection requiring systemic therapy",
"criterion": "active infection",
"requirement": {
"requirement_type": "treatment",
"expected_value": "systemic therapy"
}
},
{
"exact_snippets": "other serious infection",
"criterion": "serious infection",
"requirement": {
"requirement_type": "severity",
"expected_value": "serious"
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Active infection requiring systemic therapy",
"criterion": "active infection",
"requirement": {
"requirement_type": "treatment",
"expected_value": "systemic therapy"
}
},
{
"exact_snippets": "other serious infection",
"criterion": "serious infection",
"requirement": {
"requirement_type": "severity",
"expected_value": "serious"
}
}
]
}
},
{
"identified_line": {
"line": "* Inability to swallow oral medication",
"criterions": [
{
"exact_snippets": "Inability to swallow oral medication",
"criterion": "ability to swallow oral medication",
"requirement": {
"requirement_type": "ability",
"expected_value": true
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Inability to swallow oral medication",
"criterion": "ability to swallow oral medication",
"requirement": {
"requirement_type": "ability",
"expected_value": true
}
}
}
},
{
"identified_line": {
"line": "* Gastrointestinal (GI) disease or GI procedure that could interfere with oral absorption or tolerance of alisertib",
"criterions": [
{
"exact_snippets": "Gastrointestinal (GI) disease",
"criterion": "Gastrointestinal disease",
"requirement": {
"requirement_type": "interference with oral absorption or tolerance of alisertib",
"expected_value": true
}
},
{
"exact_snippets": "GI procedure that could interfere with oral absorption or tolerance of alisertib",
"criterion": "GI procedure",
"requirement": {
"requirement_type": "interference with oral absorption or tolerance of alisertib",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Gastrointestinal (GI) disease",
"criterion": "Gastrointestinal disease",
"requirement": {
"requirement_type": "interference with oral absorption or tolerance of alisertib",
"expected_value": true
}
},
{
"exact_snippets": "GI procedure that could interfere with oral absorption or tolerance of alisertib",
"criterion": "GI procedure",
"requirement": {
"requirement_type": "interference with oral absorption or tolerance of alisertib",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Symptomatic brain metastasis",
"criterions": [
{
"exact_snippets": "Symptomatic brain metastasis",
"criterion": "brain metastasis",
"requirement": {
"requirement_type": "symptomatic",
"expected_value": true
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Symptomatic brain metastasis",
"criterion": "brain metastasis",
"requirement": {
"requirement_type": "symptomatic",
"expected_value": true
}
}
}
},
{
"identified_line": {
"line": "* Uncontrolled cardiovascular condition",
"criterions": [
{
"exact_snippets": "Uncontrolled cardiovascular condition",
"criterion": "cardiovascular condition",
"requirement": {
"requirement_type": "control",
"expected_value": false
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Uncontrolled cardiovascular condition",
"criterion": "cardiovascular condition",
"requirement": {
"requirement_type": "control",
"expected_value": false
}
}
]
}
},
{
"identified_line": {
"line": "* Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C",
"criterions": [
{
"exact_snippets": "Known history of human immunodeficiency virus (HIV) infection",
"criterion": "HIV infection",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
},
{
"exact_snippets": "Known history of ... hepatitis B",
"criterion": "hepatitis B",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
},
{
"exact_snippets": "Known history of ... hepatitis C",
"criterion": "hepatitis C",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Known history of human immunodeficiency virus (HIV) infection",
"criterion": "HIV infection",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
},
{
"exact_snippets": "Known history of ... hepatitis B",
"criterion": "hepatitis B",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
},
{
"exact_snippets": "Known history of ... hepatitis C",
"criterion": "hepatitis C",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Lactose-intolerant (Parts A and B only)",
"criterions": [
{
"exact_snippets": "Lactose-intolerant (Parts A and B only)",
"criterion": "lactose intolerance",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Lactose-intolerant (Parts A and B only)",
"criterion": "lactose intolerance",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"or_criteria": [
{
"exact_snippets": "Lactose-intolerant (Parts A and B only)",
"criterion": "trial part",
"requirement": {
"requirement_type": "presence",
"expected_value": "A"
}
},
{
"exact_snippets": "Lactose-intolerant (Parts A and B only)",
"criterion": "trial part",
"requirement": {
"requirement_type": "presence",
"expected_value": "B"
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "* Prior history of metabolic acidosis (Parts A and B only)",
"criterions": [
{
"exact_snippets": "Prior history of metabolic acidosis",
"criterion": "metabolic acidosis",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Prior history of metabolic acidosis",
"criterion": "metabolic acidosis",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
},
{
"or_criteria": [
{
"exact_snippets": "Parts A only",
"criterion": "trial part",
"requirement": {
"requirement_type": "inclusion",
"expected_value": "A"
}
},
{
"exact_snippets": "Parts B only",
"criterion": "trial part",
"requirement": {
"requirement_type": "inclusion",
"expected_value": "B"
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "* A medical condition requiring use of pancreatic enzymes; or daily, chronic , or regular use of proton pump inhibitors (PPI); or histamine (H2) receptor antagonists. Participants who intermittently use these medications must meet the following:",
"criterions": [
{
"exact_snippets": "medical condition requiring use of pancreatic enzymes",
"criterion": "medical condition",
"requirement": {
"requirement_type": "use of pancreatic enzymes",
"expected_value": true
}
},
{
"exact_snippets": "daily, chronic , or regular use of proton pump inhibitors (PPI)",
"criterion": "use of proton pump inhibitors (PPI)",
"requirement": {
"requirement_type": "frequency",
"expected_value": [
"daily",
"chronic",
"regular"
]
}
},
{
"exact_snippets": "use of ... histamine (H2) receptor antagonists",
"criterion": "use of histamine (H2) receptor antagonists",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "medical condition requiring use of pancreatic enzymes",
"criterion": "medical condition",
"requirement": {
"requirement_type": "use of pancreatic enzymes",
"expected_value": true
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "daily, chronic , or regular use of proton pump inhibitors (PPI)",
"criterion": "use of proton pump inhibitors (PPI)",
"requirement": {
"requirement_type": "frequency",
"expected_value": [
"daily",
"chronic",
"regular"
]
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "use of ... histamine (H2) receptor antagonists",
"criterion": "use of histamine (H2) receptor antagonists",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* No use of PPI within 7 days of first dose of alisertib",
"criterions": [
{
"exact_snippets": "No use of PPI within 7 days of first dose of alisertib",
"criterion": "PPI use",
"requirement": {
"requirement_type": "time since last use",
"expected_value": {
"operator": ">=",
"value": 7,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "No use of PPI within 7 days of first dose of alisertib",
"criterion": "PPI use",
"requirement": {
"requirement_type": "time since last use",
"expected_value": {
"operator": ">=",
"value": 7,
"unit": "days"
}
}
}
}
},
{
"identified_line": {
"line": "* No use of H2 antagonist or pancreatic enzymes within 24 hours of first dose of alisertib",
"criterions": [
{
"exact_snippets": "No use of H2 antagonist",
"criterion": "H2 antagonist use",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No use of ... pancreatic enzymes",
"criterion": "pancreatic enzyme use",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "within 24 hours of first dose of alisertib",
"criterion": "time since last use of H2 antagonist or pancreatic enzymes",
"requirement": {
"requirement_type": "time",
"expected_value": {
"operator": "<",
"value": 24,
"unit": "hours"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "No use of H2 antagonist",
"criterion": "H2 antagonist use",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "within 24 hours of first dose of alisertib",
"criterion": "time since last use of H2 antagonist or pancreatic enzymes",
"requirement": {
"requirement_type": "time",
"expected_value": {
"operator": "<",
"value": 24,
"unit": "hours"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "No use of ... pancreatic enzymes",
"criterion": "pancreatic enzyme use",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "within 24 hours of first dose of alisertib",
"criterion": "time since last use of H2 antagonist or pancreatic enzymes",
"requirement": {
"requirement_type": "time",
"expected_value": {
"operator": "<",
"value": 24,
"unit": "hours"
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Participants requiring full systemic anticoagulation",
"criterions": [
{
"exact_snippets": "Participants requiring full systemic anticoagulation",
"criterion": "systemic anticoagulation",
"requirement": {
"requirement_type": "necessity",
"expected_value": true
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Participants requiring full systemic anticoagulation",
"criterion": "systemic anticoagulation",
"requirement": {
"requirement_type": "necessity",
"expected_value": true
}
}
}
},
{
"identified_line": {
"line": "Participants meeting any of the following exclusion criteria are not to be enrolled in the study:",
"criterions": []
},
"logical_structure": {
"or_criteria": []
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"identified_line": {
"line": "* Histologically or cytologically confirmed metastatic and/or advanced solid tumor",
"criterions": [
{
"exact_snippets": "Histologically or cytologically confirmed",
"criterion": "tumor confirmation method",
"requirement": {
"requirement_type": "method",
"expected_value": [
"histologically",
"cytologically"
]
}
},
{
"exact_snippets": "metastatic and/or advanced solid tumor",
"criterion": "tumor stage",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"metastatic",
"advanced"
]
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"or_criteria": [
{
"exact_snippets": "Histologically or cytologically confirmed",
"criterion": "tumor confirmation method",
"requirement": {
"requirement_type": "method",
"expected_value": [
"histologically"
]
}
},
{
"exact_snippets": "Histologically or cytologically confirmed",
"criterion": "tumor confirmation method",
"requirement": {
"requirement_type": "method",
"expected_value": [
"cytologically"
]
}
}
]
},
{
"or_criteria": [
{
"exact_snippets": "metastatic and/or advanced solid tumor",
"criterion": "tumor stage",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"metastatic"
]
}
},
{
"exact_snippets": "metastatic and/or advanced solid tumor",
"criterion": "tumor stage",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"advanced"
]
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "value",
"expected_value": "0"
}
},
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "value",
"expected_value": "1"
}
}
]
}
},
{
"identified_line": {
"line": "* Voluntary written consent",
"criterions": [
{
"exact_snippets": "Voluntary written consent",
"criterion": "consent",
"requirement": {
"requirement_type": "type",
"expected_value": "voluntary written"
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
},
{
"identified_line": {
"line": "* Suitable venous access for study-required blood sampling",
"criterions": [
{
"exact_snippets": "Suitable venous access for study-required blood sampling",
"criterion": "venous access",
"requirement": {
"requirement_type": "suitability",
"expected_value": true
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
},
{
"identified_line": {
"line": "* Measurable disease",
"criterions": [
{
"exact_snippets": "Measurable disease",
"criterion": "disease",
"requirement": {
"requirement_type": "measurability",
"expected_value": true
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
},
{
"identified_line": {
"line": "* Recovered from effects of prior antineoplastic therapy",
"criterions": [
{
"exact_snippets": "Recovered from effects of prior antineoplastic therapy",
"criterion": "recovery from prior antineoplastic therapy",
"requirement": {
"requirement_type": "status",
"expected_value": "recovered"
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
},
{
"identified_line": {
"line": "* Meet required entry laboratory and organ function levels",
"criterions": [
{
"exact_snippets": "Meet required entry laboratory and organ function levels",
"criterion": "laboratory levels",
"requirement": {
"requirement_type": "levels",
"expected_value": "required entry"
}
},
{
"exact_snippets": "Meet required entry laboratory and organ function levels",
"criterion": "organ function levels",
"requirement": {
"requirement_type": "levels",
"expected_value": "required entry"
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
}
],
"failed_exclusion": [
{
"identified_line": {
"line": "* Nitrosoureas or mitomycin-C within 6 weeks before the first dose of alisertib.",
"criterions": [
{
"exact_snippets": "Nitrosoureas ... within 6 weeks before the first dose of alisertib.",
"criterion": "nitrosoureas",
"requirement": {
"requirement_type": "time since last dose",
"expected_value": {
"operator": ">=",
"value": 6,
"unit": "weeks"
}
}
},
{
"exact_snippets": "mitomycin-C within 6 weeks before the first dose of alisertib.",
"criterion": "mitomycin-C",
"requirement": {
"requirement_type": "time since last dose",
"expected_value": {
"operator": ">=",
"value": 6,
"unit": "weeks"
}
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Nitrosoureas ... within 6 weeks before the first dose of alisertib.",
"criterion": "nitrosoureas",
"requirement": {
"requirement_type": "time since last dose",
"expected_value": {
"operator": "<",
"value": 6,
"unit": "weeks"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "mitomycin-C within 6 weeks before the first dose of alisertib.",
"criterion": "mitomycin-C",
"requirement": {
"requirement_type": "time since last dose",
"expected_value": {
"operator": "<",
"value": 6,
"unit": "weeks"
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected",
"criterions": [
{
"exact_snippets": "Diagnosis ... of another malignancy within 2 years preceding first dose of study drug",
"criterion": "diagnosis of another malignancy",
"requirement": {
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "years"
}
}
},
{
"exact_snippets": "treatment of another malignancy within 2 years preceding first dose of study drug",
"criterion": "treatment of another malignancy",
"requirement": {
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "years"
}
}
},
{
"exact_snippets": "except nonmelanoma skin cancer",
"criterion": "nonmelanoma skin cancer",
"requirement": {
"requirement_type": "exclusion",
"expected_value": true
}
},
{
"exact_snippets": "except ... in situ malignancy completely resected",
"criterion": "in situ malignancy",
"requirement": {
"requirement_type": "resection status",
"expected_value": "completely resected"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Diagnosis ... of another malignancy within 2 years preceding first dose of study drug",
"criterion": "diagnosis of another malignancy",
"requirement": {
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "years"
}
}
},
{
"exact_snippets": "treatment of another malignancy within 2 years preceding first dose of study drug",
"criterion": "treatment of another malignancy",
"requirement": {
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "years"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "nonmelanoma skin cancer",
"criterion": "nonmelanoma skin cancer",
"requirement": {
"requirement_type": "exclusion",
"expected_value": true
}
},
{
"exact_snippets": "in situ malignancy",
"criterion": "in situ malignancy",
"requirement": {
"requirement_type": "resection status",
"expected_value": "completely resected"
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "* Use of enzyme-inducing antiepileptic drugs such as phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort within 14 days prior to the first dose of alisertib",
"criterions": [
{
"exact_snippets": "Use of enzyme-inducing antiepileptic drugs such as phenytoin, carbamazepine or phenobarbital",
"criterion": "enzyme-inducing antiepileptic drugs",
"requirement": {
"requirement_type": "use",
"expected_value": false
}
},
{
"exact_snippets": "rifampin, rifabutin, rifapentine or St. John's wort",
"criterion": "rifampin, rifabutin, rifapentine, St. John's wort",
"requirement": {
"requirement_type": "use",
"expected_value": false
}
},
{
"exact_snippets": "within 14 days prior to the first dose of alisertib",
"criterion": "time since last use of specified drugs",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": "<",
"value": 14,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Use of enzyme-inducing antiepileptic drugs such as phenytoin, carbamazepine or phenobarbital",
"criterion": "enzyme-inducing antiepileptic drugs",
"requirement": {
"requirement_type": "use",
"expected_value": true
}
},
{
"exact_snippets": "within 14 days prior to the first dose of alisertib",
"criterion": "time since last use of specified drugs",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": "<",
"value": 14,
"unit": "days"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "rifampin, rifabutin, rifapentine or St. John's wort",
"criterion": "rifampin, rifabutin, rifapentine, St. John's wort",
"requirement": {
"requirement_type": "use",
"expected_value": true
}
},
{
"exact_snippets": "within 14 days prior to the first dose of alisertib",
"criterion": "time since last use of specified drugs",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": "<",
"value": 14,
"unit": "days"
}
}
}
]
}
]
}
]
}
}
],
"failed_miscellaneous": []
}